Opsens Revenue and Competitors
Estimated Revenue & Valuation
- Opsens's estimated annual revenue is currently $66.5M per year.
- Opsens received $8.0M in venture funding in March 2019.
- Opsens's estimated revenue per employee is $313,750
- Opsens's total funding is $64.7M.
Employee Data
- Opsens has 212 Employees.
- Opsens grew their employee count by 0% last year.
Opsens's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Commercial Officer | Reveal Email/Phone |
2 | Senior R&D Director - New Products Development | Reveal Email/Phone |
3 | Director Sales and Clinical Development EMEA & Japan | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Director, New Business Development | Reveal Email/Phone |
7 | Manager, Human Resources-Commercial Operations | Reveal Email/Phone |
8 | Gestionnaire de projet / Project Manager | Reveal Email/Phone |
9 | Territory Manager | Reveal Email/Phone |
10 | Customer Service Manager and Data Entry | Reveal Email/Phone |
Opsens Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.6M | 21 | -32% | $26.7M | N/A |
#2 | $45.4M | 181 | 12% | N/A | N/A |
#3 | $0.5M | 4 | -80% | $4M | N/A |
#4 | $90.9M | 362 | 9% | N/A | N/A |
#5 | $11.3M | 45 | 45% | N/A | N/A |
#6 | $12.6M | 50 | 4% | N/A | N/A |
#7 | $46.9M | 187 | -18% | N/A | N/A |
#8 | $6.5M | 26 | 8% | N/A | N/A |
#9 | $66.5M | 212 | 0% | $64.7M | N/A |
#10 | $33.1M | 132 | 8% | N/A | N/A |
What Is Opsens?
Opsens focuses on the measure of FFR in interventional cardiology, offering an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other industrial applications. Opsens aims to become a key player in the FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented technologies. Immune to the adverse effects related to blood contact, it allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. It is also designed to provide cardiologists with optimized performances to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 M in sales in 2014. It is expected to reach US$1 B med-term. Opsens Solutions, a leading manufacturer of fiber optic sensors, presents its latest advances with its White-Light Polarization Interferometry (WLPI) technology and its SemiConductor Band Gap (SCBG) technology. With several new sensor models, Opsens Solutions provides high-accuracy, high-stability measurements, and high-resolution detection solutions to meet the needs of industries such as: Downhole fiber optic pressure and temperature sensor for Oil and Gas Temperature & pressure monitoring for Energy-related applications Precise instrumentation for Defense and Aerospace Customized OEM fiber optic sensor solutions Our technology can measure temperature, pressure, linear displacement, constraint, force and load. Our sensors perform in many harsh environments and at high temperatures. They are also insensitive to RF radiation, MRI, EMI, nuclear and microwave.
keywords:Agriculture,Cleantech,Hardware,Hardware Peripherals,Healthcare,Medical Devices,Pharmaceuticals,Solar Power,Wind Power$64.7M
Total Funding
212
Number of Employees
$66.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Opsens News
Get Opsens alerts: On Thursday, January 27th, Robin Villeneuve sold 50,000 shares of Opsens stock. The stock was sold at...
QUEBEC, April 13, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused...
Good morning, everyone, and thank you all for joining us today for the OpSens second quarter fiscal year 2022 conference call for the period...
Conference call on the results today at 11 a.m. ET QUEBEC CITY, Nov. 23, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported ...
Conference call on the results to be held today at 11 a.m. QUEBEC CITY, July 13, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical tech ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $35.3M | 228 | -68% | N/A |
#2 | $37M | 232 | 8% | N/A |
#3 | $99.2M | 372 | 6% | $46.2M |
#4 | $62.5M | 490 | 0% | N/A |
#5 | $129.9M | 495 | 8% | N/A |
Opsens Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2019-03-01 | $8.0M | Undisclosed | CIBC Innovation Banking | Article |